

Market Announcement

6 June 2024

LTR Pharma Limited (ASX: LTP) – Suspension from Quotation

Description

The securities of LTR Pharma Limited ('LTP') will be suspended from quotation immediately under Listing Rule 17.2, at the request of LTP, pending the release of an announcement regarding the results of a primary and secondary clinical study.

Issued by

ASX Compliance



6 June 2024

Melissa Kostopoulos
ASX Compliance Pty Limited
Level 4, North Tower, Rialto
525 Collins Street
Melbourne VIC 3000

By email: tradinghaltsmelbourne@asx.com.au

Dear Melissa

LTR Pharma Limited (ASX: LTP) – Request for Voluntary Suspension

In accordance with ASX Listing Rule 17.2, LTR Pharma Limited ACN 644 924 569 (Company) requests a voluntary suspension with respect to the Company's securities quoted on the Australian Securities Exchange effective immediately, pending the release of an announcement in relation to the achievement of clinical study results.

The voluntary suspension is requested until the release of an announcement regarding the clinical study results which is expected to be made by market open on Friday 7 June 2024.

The Company is not aware of any reason why the voluntary suspension should not be granted.

Kind regards

Belinda Cleminson
Company Secretary

About LTR Pharma

LTR Pharma is focused on improving men's health, physically and mentally, through the commercialisation of an innovative nasal spray treatment for Erectile Dysfunction. ED is a pressing health issue for millions of men that can negatively impact self-esteem and relationships, across multiple age brackets. LTR Pharma's lead product SPONTAN® is set apart from existing ED therapies by its mechanism of action – intranasal delivery technology of a PDE5 inhibitor. The nasal cavity is a highly vascular part of the body supporting even and rapid absorption of the drug, empowering it to work within 10 minutes or less. LTR Pharma is proudly aiming to restore greater control over the timing, spontaneity, and enjoyment of sexual experiences.